Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when TNXP files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsTonix shareholders authorize reverse stock split up to 1-for-250, approve equity plan
Filed May 7, 2026 · Period ending May 7, 2026 · ~1 min read
Key Changes
-
high
Board granted authority to execute reverse stock splits at ratios between 1:2 and 1:250 within two years, with full discretion on timing. Often used to maintain exchange listing requirements when share price falls too low.
Item 5.07 verify on EDGAR → -
medium
Shareholders approved 2026 Stock Incentive Plan, creating new pool of shares for employee and director compensation. Vote was closer than other proposals (2.0M for vs 1.6M against), indicating some shareholder concern about dilution.
Item 5.07 verify on EDGAR → -
low
Annual meeting achieved 54% quorum with all nine director nominees re-elected and PwC ratified as auditor for 2026. Routine governance matters with no contested votes.
Item 5.07 verify on EDGAR →
Summary
Tonix shareholders granted the board sweeping authority to execute reverse stock splits at any ratio up to 1-for-250 over the next two years. This is a significant development that suggests the company may be preparing to address compliance issues with exchange listing requirements, which typically mandate minimum share prices.
The wide ratio range (up to 250-to-1) gives management maximum flexibility but could dramatically reduce share count if executed at the high end. The meeting also approved a new stock incentive plan that will enable equity-based compensation for employees and directors.
While standard practice for biotech companies competing for talent, the relatively close vote (55% approval) suggests meaningful shareholder concern about dilution from new equity awards. Retail investors should monitor for any announcement of actual reverse split execution, which would be disclosed via 8-K. The company's share price trajectory and any Nasdaq compliance notices will signal whether and when the board exercises this new authority.
Section-by-Section Diff
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On May 7, 2026, Tonix Pharmaceuticals Holding Corp. (the “Company”) held its annual meeting of shareholders (“Annual Meeting”). At the Annual Meeting, the shareholders of the Company approved the Company’s 2026 Stock Incentive Plan (the “Plan”)
Shareholders voted to approve a new stock incentive plan at the 2026 annual meeting. This plan will allow the company to grant equity-based compensation to employees, directors, and consultants. The approval enables the company to use stock options, restricted stock, and other equity awards as part of its compensation strategy.
Event · Item 5.07 — Submission of Matters to a Vote of Security Holders
Tonix held its 2026 Annual Meeting, approving director elections, auditor ratification, reverse stock split authority, and a new stock incentive plan.
Added in current filing · verify on EDGAR →
The Company’s shareholders approved a proposal to authorize the Company’s Board of Directors (the “Board”), in its discretion at any time within two years of May 7, 2026, to effect on or more reverse stock splits of then-outstanding shares of the Company’s common stock, at an aggregate ratio of not less than one-for-two (1:2) and not greater than one-for-two-hundred-and-fifty (1:250), with the exact ratio, number and timing of the reverse stock splits to be determined by the Board and included in a public announcement
Shareholders granted the Board authority to execute one or more reverse stock splits within the next two years at ratios between 1:2 and 1:250. Reverse splits reduce share count and increase per-share price, often used to maintain exchange listing requirements. The Board has full discretion on timing and ratio. The vote passed with 4,400,765 for versus 2,826,586 against.
Show 3 minor / wording changes
Added in current filing · verify on EDGAR →
The Company’s shareholders elected nine individuals to the Board of Directors
All nine director nominees were elected: Seth Lederman, Richard Bagger, Margaret Smith Bell, David Grange, James Hunter, Adeoye Olukotun, R. Newcomb Stillwell, Carolyn Taylor, and James Treco. Each received between 3.2 and 3.3 million votes for, with relatively small withhold votes. This represents continuity in board composition.
Added in current filing · verify on EDGAR →
The Company’s shareholders ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026
Shareholders overwhelmingly ratified PwC as the independent auditor for 2026, with 6,910,516 votes for versus 189,838 against. This is a routine annual vote confirming the audit committee's selection and indicates no shareholder concerns about audit quality or independence.
Added in current filing · verify on EDGAR →
Shareholders representing 7,267,759 shares, or 54.22%, of the common shares outstanding as of the March 19, 2026, record date, were represented at the meeting by proxy.
The Annual Meeting achieved a 54.22% quorum with 7.3 million shares represented. This is a typical attendance level for small-cap companies where most voting occurs by proxy rather than in-person attendance.
Event · Item 9.01 — Financial Statements and Exhibits
Item 9.01 — Financial Statements and Exhibits filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
Tonix Pharmaceuticals Holding Corp. 2026 Stock Incentive Plan, incorporated herein by reference to Annex A to our Definitive Proxy Statement on Schedule 14A (File No. 001-36019), filed with the Commission on March 30, 2026
The company has formally incorporated its 2026 Stock Incentive Plan into this 8-K filing. This plan, previously disclosed in the proxy statement filed March 30, 2026, was likely approved by shareholders at the annual meeting. Stock incentive plans authorize the issuance of equity compensation to employees, directors, and consultants, which can dilute existing shareholders but is a standard mechanism for aligning management interests with shareholder value.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 1, 2026 · How we verify